Tempest Therapeutics Inc (TPST) News & EventsTPSTTempest Therapeutics Inc

Tempest Therapeutics Completes Private Placement of 3.1 Million Shares

Tempest Therapeutics announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock, series C warrants to purchase up to 3,105,591 shares of common stock and series D warrants to purchase up to 3,105,591 shares of common stock, at a combined purchase price of 80.5c per share of common stock and accompanying warrants in a private placement. The series C warrants and the series D warrants will have an exercise price of 80.5c per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants. The series C warrants will expire six years from the later of the Stockholder Approval Date and the Effectiveness Date and the series D warrants will expire three years from the later of the Stockholder Approval Date and the Effectiveness Date. The private placement is expected to close on or about September 14, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Selling Stockholders Plan to Sell Up to 8.91M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.91M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.